person · Reporting owner

Squarer Ron

Disclosed activity across 5 companies

Tapewire entity: 30346
SEC CIK: 0001454001

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ADC Therapeutics SAADCT · Entity 6502	Director	June 01, 2026	June 03, 2026
Travere Therapeutics, Inc.TVTX · Entity 1562	Director	May 19, 2026	May 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADC Therapeutics SA

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	123,431	Ending reported balance After 2026-06-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-01 · Grant · Acquired 45,000 · Balance 138,627 F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-03 · Tax withholding · Disposed 15,196 · Balance 123,431 F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Travere Therapeutics, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	39,375	Reported balance After 2026-05-19 transaction · row 1 1 source row Row 1 · 2026-05-19 · Grant · Acquired 4,000 · Balance 39,375 F1: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2: The equity award vests over a one year period.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.26 · Expires 2036-05-19	Direct	12,000	Reported balance After 2026-05-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-19 · Grant · Acquired 12,000 · Balance 12,000 F1: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2: The equity award vests over a one year period.

Filing footnotes · ownership attribution and instrument terms

F1: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2: The equity award vests over a one year period.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARRAY BIOPHARMA INC

Report date July 30, 2019 · Filed July 30, 2019

Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-07-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-07-30 · Disposition to issuer · Disposed 259,891 · Balance 442,190 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 442,190 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2022-04-26	Direct	Reported balance After 2019-07-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-30 · Disposition to issuer · Disposed 545,820 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on April 26, 2013.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 · Expires 2024-04-01	Direct	Reported balance After 2019-07-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-07-30 · Disposition to issuer · Disposed 345,312 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on April 1, 2015.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2025-04-01	Direct	Reported balance After 2019-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-07-30 · Disposition to issuer · Disposed 113,438 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7: The option provided for vesting in four equal annual installments beginning on April 1, 2016.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-04-01	Direct	Reported balance After 2019-07-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-07-30 · Disposition to issuer · Disposed 453,750 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F8: The option provided for vesting in four equal annual installments beginning on April 1, 2017.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2026-12-27	Direct	Reported balance After 2019-07-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-07-30 · Disposition to issuer · Disposed 421,875 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F9: The option provided for vesting in four equal annual installments beginning on December 26, 2017.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.92 · Expires 2027-12-16	Direct	Reported balance After 2019-07-30 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-07-30 · Disposition to issuer · Disposed 600,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F10: The option provided for vesting in four equal annual installments beginning on December 16, 2018.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.97 · Expires 2028-12-16	Direct	Reported balance After 2019-07-30 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-07-30 · Disposition to issuer · Disposed 678,750 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F11: The option provided for vesting in four equal annual installments beginning on December 16, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.

F4: The option provided for vesting in four equal annual installments beginning on April 26, 2013.

F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F6: The option provided for vesting in four equal annual installments beginning on April 1, 2015.

F7: The option provided for vesting in four equal annual installments beginning on April 1, 2016.

F8: The option provided for vesting in four equal annual installments beginning on April 1, 2017.

F9: The option provided for vesting in four equal annual installments beginning on December 26, 2017.

F10: The option provided for vesting in four equal annual installments beginning on December 16, 2018.

F11: The option provided for vesting in four equal annual installments beginning on December 16, 2019.

Deciphera Pharmaceuticals, Inc.

Report date June 11, 2024 · Filed June 12, 2024

Section 16 reporting ended · disclosed 2024-06-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27	Direct	Reported balance After 2024-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-11 · Disposition to issuer · Disposed 9,570 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98	Direct	Reported balance After 2024-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-06-11 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.27	Direct	Reported balance After 2024-06-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-06-11 · Disposition to issuer · Disposed 3,269 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.91	Direct	Reported balance After 2024-06-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-06-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.46	Direct	Reported balance After 2024-06-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-06-11 · Disposition to issuer · Disposed 4,727 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

Nuvalent, Inc.

Report date July 15, 2026 · Filed July 15, 2026

Section 16 reporting ended · disclosed 2026-07-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common Stock - Restricted Stock UnitsSEC Table I · non-derivative	Direct	0	Reported balance After 2026-07-15 transaction · row 1 1 source row Row 1 · 2026-07-15 · Disposition to issuer · Disposed 6,281 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), F2: (Continued from footnote 1) subject to applicable withholding tax. After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F3: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company. F4: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $105.74 · Expires 2035-12-10	Direct	0	Reported balance After 2026-07-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-15 · Disposition to issuer · Disposed 4,418 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"),

F2: (Continued from footnote 1) subject to applicable withholding tax. After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F3: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company.

F4: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.

F5: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 08, 2019 Filed May 11, 2019 00:38 UTC	Travere Therapeutics, Inc. RTRX · Entity 1562	GrantEmployee stock option (right to buy) · Derivative	8,000	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0001209191-19-029159 · doc4.xml · derivative · entry 2 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document
May 08, 2019 Filed May 11, 2019 00:38 UTC	Travere Therapeutics, Inc. RTRX · Entity 1562	GrantCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-029159 · doc4.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,875 Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:31 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	18,906	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-19-002183 · primarydocument.xml · derivative · entry 4 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,907 Underlying: Common Stock · 18,906 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2016. F4 · derivative.expiration_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2016. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:31 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	18,907	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-19-002183 · primarydocument.xml · derivative · entry 3 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The RSUs vested and settled in stock in four equal annual installments beginning April 1, 2015. F3 · derivative.expiration_date: The RSUs vested and settled in stock in four equal annual installments beginning April 1, 2015. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:31 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	16,631	$24.60	$409,122.60	Disclosure SEC source: 0001562180-19-002183 · primarydocument.xml · nonDerivative · entry 2 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,891 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:31 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	37,813	$0.00	$0.00	Disclosure SEC source: 0001562180-19-002183 · primarydocument.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on April 1, 2015 and April 1, 2016, as a result of the vesting of one fourth of such RSUs. Read SEC document
February 07, 2019 Filed Feb 8, 2019 18:31 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	110,000	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0001562180-19-000859 · primarydocument.xml · derivative · entry 3 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,820 Underlying: Common Stock · 110,000 shares Expires 2022-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on April 26, 2013. Read SEC document
February 07, 2019 Filed Feb 8, 2019 18:31 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	110,000	$21.64	$2,380,015.00	Disclosure SEC source: 0001562180-19-000859 · primarydocument.xml · nonDerivative · entry 2 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,709 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $21.50 to $21.80. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
February 07, 2019 Filed Feb 8, 2019 18:31 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	110,000	$3.61	$397,100.00	Disclosure SEC source: 0001562180-19-000859 · primarydocument.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 31, 2019 Filed Feb 1, 2019 20:44 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	113,438	$0.00 Strike: $7.30	$0.00	Disclosure SEC source: 0001562180-19-000687 · primarydocument.xml · derivative · entry 6 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,438 Underlying: Common Stock · 113,438 shares Expires 2025-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in four equal annual installments beginning on April 1, 2016. Read SEC document
January 31, 2019 Filed Feb 1, 2019 20:44 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	113,438	$18.53	$2,101,541.04	Disclosure SEC source: 0001562180-19-000687 · primarydocument.xml · nonDerivative · entry 4 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,709 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $18.50 to $18.605. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
January 31, 2019 Filed Feb 1, 2019 20:44 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	113,438	$7.30	$828,097.40	Disclosure SEC source: 0001562180-19-000687 · primarydocument.xml · nonDerivative · entry 3 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 30, 2019 Filed Feb 1, 2019 20:44 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0001562180-19-000687 · primarydocument.xml · derivative · entry 5 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,820 Underlying: Common Stock · 100,000 shares Expires 2022-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on April 26, 2013. Read SEC document
January 30, 2019 Filed Feb 1, 2019 20:44 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	100,000	$18.25	$1,825,370.00	Disclosure SEC source: 0001562180-19-000687 · primarydocument.xml · nonDerivative · entry 2 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,709 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $18.25 to $18.29. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
January 30, 2019 Filed Feb 1, 2019 20:44 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	100,000	$3.61	$361,000.00	Disclosure SEC source: 0001562180-19-000687 · primarydocument.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	25,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005027 · primarydocument.xml · derivative · entry 6 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2021-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	23,437	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005027 · primarydocument.xml · derivative · entry 5 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,876 Underlying: Common Stock · 23,437 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	21,303	$15.97	$340,208.91	Disclosure SEC source: 0001562180-18-005027 · primarydocument.xml · nonDerivative · entry 2 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,709 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
December 16, 2018 Filed Dec 18, 2018 19:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	48,437	$0.00	$0.00	Disclosure SEC source: 0001562180-18-005027 · primarydocument.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs. Read SEC document
December 14, 2018 Filed Dec 18, 2018 19:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	GrantStock Option (Right to Buy) · Derivative	678,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005027 · primarydocument.xml · derivative · entry 4 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,750 Underlying: Common Stock · 678,750 shares Expires 2028-12-16 F4 · derivative.exercise_date: The options vest in four equal annual installments beginning on December 16, 2019. Read SEC document
December 14, 2018 Filed Dec 18, 2018 19:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	GrantRestricted Stock Units · Derivative	113,125	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-005027 · primarydocument.xml · derivative · entry 3 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,125 Underlying: Common Stock · 113,125 shares Expires 2022-12-20 F3 · derivative.exercise_date: RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive once share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:22 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	140,625	$0.00 Strike: $8.79	$0.00	Disclosure SEC source: 0001562180-18-003129 · primarydocument.xml · derivative · entry 7 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,875 Underlying: Common Stock · 140,625 shares Expires 2026-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The options vest in four equal annual installments beginning on December 16, 2017. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:22 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	77,881	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-003129 · primarydocument.xml · derivative · entry 6 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,881 shares Expires 2018-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: RSUs representing 77,881 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:22 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	140,625	$18.03	$2,535,468.75	Disclosure SEC source: 0001562180-18-003129 · primarydocument.xml · nonDerivative · entry 5 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,575 F3 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $17.35 to $18.79. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:22 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	140,625	$8.79	$1,236,093.75	Disclosure SEC source: 0001562180-18-003129 · primarydocument.xml · nonDerivative · entry 4 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares released on vesting of Restricted Stock Units ("RSUs") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:22 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	43,628	$17.74	$773,960.72	Disclosure SEC source: 0001562180-18-003129 · primarydocument.xml · nonDerivative · entry 3 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,575 F3 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $17.60 to $17.84. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:22 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	34,253	$18.50	$633,680.50	Disclosure SEC source: 0001562180-18-003129 · primarydocument.xml · nonDerivative · entry 2 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,203 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:22 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	77,881	$0.00	$0.00	Disclosure SEC source: 0001562180-18-003129 · primarydocument.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares released on vesting of Restricted Stock Units ("RSUs") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II. Read SEC document
May 09, 2018 Filed May 12, 2018 01:11 UTC	Travere Therapeutics, Inc. RTRX · Entity 1562	GrantEmployee Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $26.52	$0.00	Disclosure SEC source: 0001209191-18-029725 · doc4.xml · derivative · entry 2 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document
May 09, 2018 Filed May 12, 2018 01:11 UTC	Travere Therapeutics, Inc. RTRX · Entity 1562	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-18-029725 · doc4.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,875 Read SEC document
April 01, 2018 Filed Apr 3, 2018 18:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	18,906	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-18-001802 · primarydocument.xml · derivative · entry 3 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,813 Underlying: Common Stock · 18,906 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The remaining RSUs vest and will be settled in stock in two equal annual installments on April 1, 2019 and 2020. Read SEC document
April 01, 2018 Filed Apr 3, 2018 18:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Tax withholdingCommon Stock	16,605	$16.32	$270,993.60	Disclosure SEC source: 0001562180-18-001802 · primarydocument.xml · nonDerivative · entry 2 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,575 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document
April 01, 2018 Filed Apr 3, 2018 18:48 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	18,906	$0.00	$0.00	Disclosure SEC source: 0001562180-18-001802 · primarydocument.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on April 1, 2016 as a result of the vesting of one fourth of such RSUs. F2 · balance_after: Includes (i) 18,906 unvested Restricted Stock Units ("RSUs") awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and (ii) 18,906 shares of common stock issued upon the vesting of these RSU's on April 1, 2018. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	333,165	$0.00 Strike: $5.94	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 19 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 333,165 shares Expires 2023-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The option vested in four equal annual installments beginning on May 3, 2014. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	79,688	$0.00 Strike: $4.63	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 18 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,312 Underlying: Common Stock · 79,688 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vests in four equal annual installments beginning on April 1, 2015. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	133,380	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 17 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,820 Underlying: Common Stock · 133,380 shares Expires 2022-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vested in four equal annual installments beginning on April 26, 2013. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	546,233	$10.93	$5,970,326.69	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · nonDerivative · entry 10 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,274 F5 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	333,165	$5.94	$1,979,000.10	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · nonDerivative · entry 9 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	79,688	$4.63	$368,955.44	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · nonDerivative · entry 8 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	133,380	$3.61	$481,501.80	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · nonDerivative · entry 7 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	110,800	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 16 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,800 shares Expires 2022-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vested in four equal annual installments beginning on April 26, 2013. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	16,835	$0.00 Strike: $5.94	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 15 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,835 shares Expires 2023-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionStock Option (Right to Buy) · Derivative	226,874	$0.00 Strike: $7.30	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 14 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,876 Underlying: Common Stock · 226,874 shares Expires 2025-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in four equal annual installments beginning on April 1, 2016. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	SaleCommon Stock	273,438	$10.73	$2,933,989.74	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · nonDerivative · entry 6 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,274 F5 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	110,800	$3.61	$399,988.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · nonDerivative · entry 5 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	16,835	$5.94	$99,999.90	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · nonDerivative · entry 4 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionCommon Stock	226,874	$7.30	$1,656,180.20	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · nonDerivative · entry 3 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document
December 16, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	GrantStock Option (Right to Buy) · Derivative	600,000	$0.00 Strike: $10.92	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 13 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2027-12-16 F10 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 16, 2018. Read SEC document
December 16, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	GrantRestricted Stock Units · Derivative	100,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 12 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2021-12-17 F9 · derivative.exercise_date: Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018. Read SEC document
December 16, 2017 Filed Dec 19, 2017 21:05 UTC	ARRAY BIOPHARMA INC ARRY · Entity 155788	Exercise / conversionRestricted Stock Units · Derivative	23,437	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-17-003955 · primarydocument.xml · derivative · entry 11 Squarer Ron · CIK 0001454001 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,313 Underlying: Common Stock · 23,437 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The RSUs vested on December 16, 2017. F8 · balance_after: Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.